Physician profile
Danwen Yang
NPI 1154740306
$6,711.23
in general payments reported to CMS, 2019-2025
26 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $335 · 2021: $659 · 2022: $1,329 · 2023: $1,271 · 2024: $1,454 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191 · Education: $21.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.81 |
| Education | $21.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $870.92 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $851.99 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $525.23 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $513.29 | 2020-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $442.91 | 2022-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $388.55 | 2020-2025 | Jynarque |
| Novo Nordisk INC | $324.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Akebia Therapeutics INC | $317.89 | 2021-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $300.03 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $266.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $263.66 | 2021-2025 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $231.05 | 2019-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.81 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $220.64 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $196.98 | 2021-2025 | Velphoro, Velphoro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $185.90 | 2021-2025 | Lupkynis |
| Xeris Pharmaceuticals, INC. | $149.61 | 2021-2025 | Keveyis, Gvoke Hypopen |
| Genzyme Corporation | $141.24 | 2021-2025 | |
| Kyowa Kirin, INC. | $61.32 | 2023-2024 | Crysvita |
| Horizon Therapeutics Plc | $57.02 | 2022-2023 | Krystexxa |
| Alnylam Pharmaceuticals INC. | $48.39 | 2021-2025 | Givlaari |
| Lilly USA, LLC | $40.46 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $33.04 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $21.55 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.98 | 2024 | |
| Cormedix INC. | $18.40 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danwen Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.